Internal Medicine, Endocrinology, Diabetes, & Metabolism · Tampa, FL
NPI
1194775817
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
2727 West Martin Luther King Blvd, 450
Tampa, FL, 33607
Phone (813) 875-8453
Groups this clinician bills Medicare through
Medicare paid, 2024
$126K
2,674 services
Medicare patients, 2024
535
Average age 75
Drug cost, 2024
$2.3M
4,696 prescriptions
Company payments, 2025
$45K
From 33 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Manuel C Sainz de la Pena was code J0897 (injection, denosumab, 1 mg), 1,500 times for 18 patients. In total Manuel C Sainz de la Pena billed 2,674 services in 18 codes, and Medicare paid $126K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-08-27.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 1,500 | 18 | $20.47 | $31K |
| 99214 Office E&M - Established | Office | 522 | 341 | $88.70 | $46K |
| 99232 Hospital E&M - Subsequent | Facility | 196 | 80 | $61.26 | $12K |
| 95251 Test - Miscellaneous | Office | 120 | 72 | $25.89 | $3,107 |
| 99215 Office E&M - Established | Office | 86 | 69 | $128.63 | $11K |
| 99204 Office E&M - New | Office | 74 | 74 | $124.16 | $9,188 |
| 99222 Hospital E&M - Initial | Facility | 63 | 61 | $101.93 | $6,422 |
| 83036 Blood Count | Office | 28 | 26 | $9.52 | $267 |
| 95800 Sleep Study | Office | 28 | 28 | $72.72 | $2,036 |
| 96401 Chemotherapy Administration | Office | 24 | 18 | $44.65 | $1,072 |
| 99205 Office E&M - New | Office | 17 | 17 | $151.80 | $2,581 |
By year: 2022 $127K for 3,205 services; 2023 $134K for 2,864 services; 2024 $126K for 2,674 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 83036 Blood Count | 28 | 26 | $9.52 | $267 |
Medicare prescription drug claims, 2024
In 2024, the drug Manuel C Sainz de la Pena prescribed most often to Medicare patients was Levothyroxine Sodium, with 678 prescriptions and refills. In total Manuel C Sainz de la Pena wrote 4,696 Medicare prescriptions that cost $2.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 678 | 1,877 | 199 | $6,789 |
| Pioglitazone Hcl Generic | 477 | 1,372 | 153 | $4,145 |
| Ozempic Semaglutide | 312 | 596 | 82 | $565K |
| Metformin Hcl Generic | 235 | 636 | 72 | $1,272 |
| Rosuvastatin Calcium Generic | 230 | 680 | 80 | $2,411 |
| Jardiance Empagliflozin | 187 | 421 | 58 | $241K |
| Farxiga Dapagliflozin Propanediol | 151 | 336 | 40 | $183K |
| Atorvastatin Calcium Generic | 150 | 405 | 48 | $1,069 |
| Rybelsus Semaglutide | 105 | 210 | 36 | $197K |
| Synthroid Levothyroxine Sodium | 102 | 282 | 31 | $9,666 |
| Novolog Flexpen Insulin Aspart | 97 | 240 | 42 | $34K |
| Calcitriol Generic | 84 | 210 | 25 | $1,935 |
| Tresiba Flextouch U-200 Insulin Degludec | 84 | 193 | 26 | $81K |
| Alendronate Sodium Generic | 83 | 181 | 25 | $866 |
| Trulicity Dulaglutide | 76 | 110 | 15 | $105K |
Brand drugs: 2,314 claims; generic drugs: 2,090 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Manuel C Sainz de la Pena $45K ($45K in general payments such as food, travel and fees) from 33 companies. The largest payer was Novo Nordisk Inc with $39K.
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc NVO | 56 | $39K |
| Abbott Laboratories ABT | 8 | $2,719 |
| Corcept Therapeutics CORT | 21 | $327 |
| Renalytix AI, Inc. | 7 | $272 |
| Amgen Inc. AMGN | 10 | $203 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 11 | $200 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 6 | $159 |
| Antares Pharma, Inc. | 6 | $143 |
| Ascendis Pharma Endocrinology Inc ASND | 6 | $143 |
| Dexcom, Inc. DXCM | 5 | $139 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.